A detailed history of American Century Companies Inc transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, American Century Companies Inc holds 59,915 shares of VTYX stock, worth $110,842. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,915
Previous 25,883 131.48%
Holding current value
$110,842
Previous $59,000 120.34%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.85 - $3.2 $62,959 - $108,902
34,032 Added 131.48%
59,915 $130,000
Q2 2024

Aug 07, 2024

BUY
$2.31 - $5.59 $59,789 - $144,685
25,883 New
25,883 $59,000
Q4 2023

Feb 13, 2024

BUY
$2.08 - $31.18 $991,207 - $14.9 Million
476,542 New
476,542 $1.18 Million
Q3 2023

Nov 13, 2023

SELL
$29.8 - $40.3 $69,225 - $93,616
-2,323 Reduced 0.93%
247,902 $8.61 Million
Q2 2023

Aug 14, 2023

BUY
$28.53 - $39.55 $29,585 - $41,013
1,037 Added 0.42%
250,225 $8.21 Million
Q1 2023

May 11, 2023

SELL
$29.51 - $46.65 $1.38 Million - $2.19 Million
-46,900 Reduced 15.84%
249,188 $8.35 Million
Q4 2022

Feb 13, 2023

SELL
$24.16 - $36.38 $50,494 - $76,034
-2,090 Reduced 0.7%
296,088 $9.71 Million
Q3 2022

Nov 14, 2022

SELL
$12.64 - $38.7 $1.58 Million - $4.82 Million
-124,607 Reduced 29.47%
298,178 $10.4 Million
Q2 2022

Aug 12, 2022

BUY
$11.95 - $18.75 $357,496 - $560,925
29,916 Added 7.61%
422,785 $5.17 Million
Q1 2022

May 11, 2022

BUY
$10.0 - $19.98 $1,190 - $2,377
119 Added 0.03%
392,869 $5.33 Million
Q4 2021

Feb 07, 2022

BUY
$14.2 - $23.07 $5.58 Million - $9.06 Million
392,750 New
392,750 $7.8 Million

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $105M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.